浙江司太立制药股份有限公司 关于选举第五届董事会职工董事的 公告

Group 1 - The company has elected Mr. Zheng Fangwei as the employee director of the fifth board of directors, with a term starting from November 24, 2025 [1][3] - The election of the employee director complies with relevant laws and regulations, ensuring that the number of employee representatives does not exceed half of the total board members [1] Group 2 - The company's wholly-owned subsidiary, Shanghai Sitaili Pharmaceutical Co., Ltd., has received a drug registration certificate for Gadopentetate Dimeglumine Injection from the National Medical Products Administration [4][5] - The drug is classified as a Class 4 chemical drug and is primarily used for magnetic resonance imaging of various organs and tissues [5][7] - The total R&D investment for this drug has reached approximately 7.07 million yuan [6] - The market data indicates that the sales of Gadopentetate Dimeglumine Injection in Chinese public medical institutions are expected to exceed 700 million yuan in 2024 [8]